Revive Therapeutics Ltd. (OTC: RVVTF), a clinical-stage company, focuses on acquiring, developing and commercializing therapeutic products. Revive’s products in phase IIa clinical trial include REV-001 for the treatment and prevention of opioid-induced respiratory depression in a perioperative setting for high-risk patients, such as persons with sleep apnea, as well as REV-002 for the treatment of gout. Revive is also involved in developing REV-003 that is in pre-clinical stage for the treatment of Rett Syndrome, a rare genetic postnatal neurological disorder; and drug Bucillamine for treating cystinuria, as well as REV-005 for the treatment of Wilson disease. For more information, visit the company’s website at www.revivethera.com.